Literature DB >> 22451343

The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.

Irene Romero1, Marisol Martinez, Cristina Garrido, Antonia Collado, Ignacio Algarra, Federico Garrido, Angel M Garcia-Lora.   

Abstract

MHC class I (MHC-I) molecules are ubiquitously expressed on the cells of an organism. Study of the regulation of these molecules in normal and disease conditions is important. In tumour cells, the expression of MHC-I molecules is very frequently lost, allowing these cells to evade the immune response. Cancers of different histology have shown total loss of MHC-I molecule expression, due to a coordinated transcriptional down-regulation of various antigen-processing machinery (APM) components and/or MHC-I heavy chains. The mechanisms responsible for these alterations remain unclear. We determined the possible genes involved by comparing MHC-I-positive with MHC-I-negative murine metastases derived from the same fibrosarcoma tumour clone. MHC-I-negative metastases showed transcriptional down-regulation of APM and MHC-I heavy chains. The use of microarrays and subtraction cDNA libraries revealed four candidate genes responsible for this alteration, but two of them were ruled out by real-time RT-PCR analyses. The other two genes, AP-2α and Fhit tumour suppressors, were studied by using siRNA to silence their expression in a MHC-I-positive metastatic cell line. AP-2α inhibition did not modify transcriptional expression of APM components or MHC-I heavy chains or surface expression of MHC-I. In contrast, silencing of the Fhit gene produced the transcriptional down-regulation of APM components and MHC-I heavy chains and decreased MHC-I surface expression. Moreover, transfection of Fhit in MHC-I-negative tumour cell lines restored MHC-I cell surface expression. These data indicate that defects in Fhit expression may promote MHC-I down-regulation in cancer cells and allow escape from immunosurveillance(#).
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451343     DOI: 10.1002/path.4029

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

Review 1.  MHC heterogeneity and response of metastases to immunotherapy.

Authors:  Ignacio Algarra; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancer Metastasis Rev       Date:  2021-04-15       Impact factor: 9.264

2.  High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.

Authors:  Evert van den Broek; Maurits J J Dijkstra; Oscar Krijgsman; Daoud Sie; Josien C Haan; Joleen J H Traets; Mark A van de Wiel; Iris D Nagtegaal; Cornelis J A Punt; Beatriz Carvalho; Bauke Ylstra; Sanne Abeln; Gerrit A Meijer; Remond J A Fijneman
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

3.  Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathway.

Authors:  Qiang Huang; Zhen Liu; Fang Xie; Chenhai Liu; Feng Shao; Cheng-lin Zhu; Sanyuan Hu
Journal:  ScientificWorldJournal       Date:  2014-03-16

Review 4.  The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.

Authors:  Wei Yan; Ning Xu; Xiang Han; Xiao-Ming Zhou; Bei He
Journal:  Sci Rep       Date:  2016-01-22       Impact factor: 4.379

Review 5.  The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.

Authors:  Xiaoyu Wu; Guannan Wu; Xuequan Yao; Gang Hou; Feng Jiang
Journal:  Drug Des Devel Ther       Date:  2016-02-15       Impact factor: 4.162

6.  MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.

Authors:  Irene Romero; Cristina Garrido; Ignacio Algarra; Virginia Chamorro; Antonia Collado; Federico Garrido; Angel M Garcia-Lora
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

7.  A novel preclinical murine model of immune-mediated metastatic dormancy.

Authors:  Irene Romero; Federico Garrido; Angel M Garcia-Lora
Journal:  Oncoimmunology       Date:  2014-06-25       Impact factor: 8.110

Review 8.  Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.

Authors:  Alexander J Stephens; Nicola A Burgess-Brown; Shisong Jiang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

Review 9.  T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy.

Authors:  Zhijian Duan; Mitchell Ho
Journal:  Mol Cancer Ther       Date:  2021-06-25       Impact factor: 6.009

Review 10.  The urgent need to recover MHC class I in cancers for effective immunotherapy.

Authors:  Federico Garrido; Natalia Aptsiauri; Elien M Doorduijn; Angel M Garcia Lora; Thorbald van Hall
Journal:  Curr Opin Immunol       Date:  2016-01-18       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.